CalciMedica Inc. (NASDAQ:CALC) Given Consensus Rating of “Hold” by Analysts

Shares of CalciMedica Inc. (NASDAQ:CALC) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $50.00.

Several research firms have recently weighed in on CALC. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday. Guggenheim initiated coverage on shares of CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th.

CalciMedica Price Performance

CalciMedica stock opened at $1.98 on Monday. The business’s 50 day simple moving average is $3.31 and its 200 day simple moving average is $3.44. CalciMedica has a 12 month low of $1.91 and a 12 month high of $36.00. The company has a market cap of $13.52 million, a price-to-earnings ratio of -0.29 and a beta of 0.83. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. Sell-side analysts forecast that CalciMedica will post -5.25 EPS for the current year.

Insider Buying and Selling

In other CalciMedica news, Director Fred A. Middleton acquired 49,794 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was bought at an average cost of $4.00 per share, with a total value of $199,176.00. Following the acquisition, the director owned 212,654 shares in the company, valued at approximately $850,616. This represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

A number of hedge funds and other institutional investors have recently bought and sold shares of CALC. Renaissance Technologies LLC lifted its position in shares of CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after acquiring an additional 18,300 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in shares of CalciMedica in the fourth quarter valued at $506,000. Envestnet Asset Management Inc. grew its position in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of CalciMedica during the 4th quarter valued at $127,000. Finally, Cetera Investment Advisers raised its stake in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the period.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.